Cenforce 100 mg (Sildenafil Citrate 100 mg)

Reliable Erectile Dysfunction Treatment

Cenforce 100 is one of the most popular and effective generic Sildenafil Citrate products on the market. Manufactured by Centurion Laboratories, it provides the same potent effects as Viagra at a fraction of the cost.

Restore your sexual confidence with a compound proven to deliver strong, sustainable erections.

Key Benefits:

• Proven Efficacy: 100mg of Sildenafil Citrate, the gold standard for ED.
• Rapid Onset: Works within 30-60 minutes.
• Long Duration: Effects last 4-6 hours.
• Cost Effective: Premium quality generic alternative.

Dosage:

• Standard Dose: 1 tablet (100mg) taken 45 minutes before activity.
• Limit: Do not exceed 1 tablet per day.

Chemical Profile

• Generic name (active moiety): sildenafil (as sildenafil citrate); marketed under the product designation Cenforce100 (each unit contains sildenafil citrate equivalent to 100 mg sildenafil).
• Chemical class: substituted pyrazolo4,3-dpyrimidinone derivative with a sulfonyl‑piperazine side chain; small‑molecule phosphodiesterase inhibitor.
• Structural description: the molecule comprises a 1,2,5‑trisubstituted pyrazolo4,3‑dpyrimidin‑7(1H)‑one core bearing a N‑methyl and N‑propyl substitution, linked through a sulfonyl moiety to a 4‑ethoxyphenyl ring, and a 1,4‑disubstituted piperazine group. The structural features responsible for activity include the heterocyclic pyrazolo‑pyrimidinone core (PDE5 binding) and the sulfonyl‑phenyl–piperazine motif that optimizes affinity and pharmacokinetic properties.
• Molecular considerations: sildenafil binds in the catalytic pocket of PDE5, forming interactions with residues in the enzyme’s active site; the molecule exhibits greater in vitro selectivity for PDE5 relative to other PDE isoenzymes (notably PDE6 in retina and PDE1 in vascular tissue) but retains measurable off‑target activity at higher concentrations.
• Average terminal plasma half‑life: approximately 3–5 hours (mean terminal half‑life ≈ 3–4 hours in healthy subjects).
• Physicochemical notes: sildenafil citrate is supplied as the citrate salt to improve aqueous solubility and stability; the citrate counter‑ion increases crystalline stability relative to the free base.

Clinical Pharmacology

Mechanism of action

• Sildenafil is a reversible competitive inhibitor of cyclic guanosine monophosphate (cGMP)‑specific phosphodiesterase type 5 (PDE5). PDE5 catalyzes degradation of cGMP in smooth muscle cells.
• In the corpus cavernosum, sexual stimulation induces nitric oxide (NO) release from nerve endings and endothelial cells, which activates guanylate cyclase and increases intracellular cGMP. By inhibiting PDE5, sildenafil reduces cGMP hydrolysis, thereby increasing intracellular cGMP concentrations, promoting protein kinase G activation, reducing intracellular Ca2+, and producing relaxation of smooth muscle in the cavernosal arteries and trabeculae. The result is augmented arterial inflow and cavernous smooth muscle relaxation that contributes to erection. Efficacy requires sexual stimulation (NO release).
• In the pulmonary vasculature, the same biochemical cascade leads to pulmonary arterial vasodilation; this underlies the use of sildenafil in pulmonary arterial hypertension at different dosing regimens.

Pharmacokinetics (summary)

• Absorption: orally administered sildenafil is rapidly absorbed; time to peak plasma concentration (Tmax) typically 0.5–2 hours (median ≈ 1 hour) in the fasted state. High‑fat meals delay Tmax and may reduce rate of absorption.
• Bioavailability: absolute oral bioavailability ≈ 40% (extensive first‑pass hepatic metabolism).
• Distribution: plasma protein binding is high (~96%) and the apparent volume of distribution is relatively large, consistent with tissue distribution.
• Metabolism: primarily hepatic via cytochrome P450 enzymes, predominantly CYP3A4 (major) and CYP2C9 (minor). The major circulating metabolite is N‑desmethylsildenafil, which retains PDE5 inhibitory activity (~40–50% of parent potency) and circulates at roughly one‑third to one‑half of parent plasma concentrations.
• Elimination: sildenafil and its metabolites are eliminated predominantly as metabolites; approximately 80% recovered in feces and ~13% in urine after oral dosing (values approximate). Renal clearance of unchanged drug is low.
• Drug interactions (pharmacokinetic/pharmacodynamic implications): coadministration with strong CYP3A4 inhibitors (e.g., certain azole antifungals, macrolide antibiotics, protease inhibitors) increases sildenafil plasma concentrations and prolongs exposure; strong CYP3A4 inducers reduce exposure. Concomitant use with nitrates or nitric oxide donors produces clinically significant hypotension through additive vasodilatory effects and is contraindicated. Use with alpha‑adrenergic blockers and antihypertensive agents warrants hemodynamic monitoring and caution due to additive blood‑pressure lowering effects.
• Pharmacodynamics: onset of pharmacodynamic effect corresponds with Tmax; duration of clinically meaningful effect is related to plasma concentration and typically corresponds to the half‑life and active metabolite exposure. Adverse effects (e.g., headache, flushing, dyspepsia, visual disturbances) are related to vasodilatory and off‑target PDE inhibition (notably PDE6 in retina).

Storage & Stability

• Recommended storage conditions: store at controlled room temperature, typically in the range of 15–30 °C (59–86 °F) unless local regulatory labeling specifies otherwise. Protect from excessive heat and direct sunlight.
• Container and moisture protection: keep in original tight, light‑resistant container to protect from moisture and light; do not store in humid environments (e.g., bathrooms).
• Physical stability: tablets/capsules are stable within labeled storage conditions for the assigned shelf life; protect film‑coated tablets from mechanical abrasion and moisture to prevent coating compromise.
• Shelf life: the product’s shelf life is established by manufacturer stability studies and specified on the packaging; stability is dependent on packaging configuration (blister vs. bottle) and storage conditions. Do not use beyond the labeled expiration date.
• Disposal: dispose of expired or unused medication according to institutional/local regulations for pharmaceutical waste; avoid environmental release.

General Information (Common medical uses)

• Primary indicated use: treatment of erectile dysfunction (ED) in adult males — sildenafil enhances erectile response to sexual stimulation by potentiating the NO‑cGMP pathway in the corpus cavernosum.
• Secondary/alternative clinical use: pulmonary arterial hypertension (PAH) — sildenafil has vasodilatory effects in the pulmonary vasculature and is used in specific formulations and dosing regimens approved for PAH; dosing and formulation differ from those used for ED.
• Off‑label and investigational uses: various investigational or off‑label vascular and endothelial disorders have been explored due to sildenafil’s vasodilatory and endothelial‑modulating properties; such uses depend on clinical evidence, regulatory approval, and specialist guidance.
• Safety considerations (brief): sildenafil is contraindicated in patients taking organic nitrates and in individuals with known hypersensitivity to sildenafil or excipients. Clinical assessment of cardiovascular status is recommended prior to use because sexual activity and vasodilator therapy impose cardiac demand. Dose adjustments or avoidance may be required in severe renal or hepatic impairment and when coadministered with interacting medications.
• Formulation: Cenforce100 is presented as an oral dosage form designed to deliver 100 mg sildenafil per unit; refer to product labeling for excipient content, tablet coating characteristics, and regulatory information.

Note: This monograph summarizes biochemical, pharmacokinetic, and clinical attributes of sildenafil at a 100 mg dosage form (marketed under the Cenforce100 designation). For prescribing, contraindications, dosing adjustments, and patient‑specific considerations, refer to locally approved prescribing information and institutional protocols.